Publications dans lesquelles il/elle collabore avec María Eugenia Pachón Ibáñez (16)

2024

  1. Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models of Escherichia coli and Acinetobacter baumannii

    Antibiotics, Vol. 13, Núm. 5

2020

  1. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: Study protocol for the prospective multicentre OptimBioma study

    BMJ Open, Vol. 10, Núm. 7

  2. In silico discovery of Acinetobacter baumannii genes involved in microaerobiosis resistance

    Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria, Núm. 9

2019

  1. Pangenome of acinetobacter baumannii uncovers two groups of genomes, one of them with genes involved in CRISPR/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation

    Microbial Genomics, Vol. 5, Núm. 11

2018

  1. Effect of hypoxia on the pathogenesis of acinetobacter baumannii and pseudomonas aeruginosa in vitro and in murine experimental models of infection

    Infection and Immunity, Vol. 86, Núm. 10

  2. Efficacy of colistin and its combination with rifampin in Vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae

    Frontiers in Microbiology, Vol. 9, Núm. MAY

  3. Intracellular trafficking and persistence of Acinetobacter baumannii requires transcription factor EB

    mSphere, Vol. 3, Núm. 2

  4. Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: Mechanistic analysis and in vivo efficacy

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 12, pp. 3405-3412

2017

  1. Combating virulence of Gram-negative bacilli by OmpA inhibition

    Scientific Reports, Vol. 7, Núm. 1

  2. Overproduction of Outer membrane protein a by Acinetobacter baumannii as a risk factor for nosocomial pneumonia, bacteremia, and mortality rate increase

    Journal of Infectious Diseases, Vol. 215, Núm. 6, pp. 966-974

  3. Perspectives for clinical use of engineered human host defense antimicrobial peptides

    FEMS Microbiology Reviews, Vol. 41, Núm. 3, pp. 323-342

2016

  1. Draft genome sequences of seven multidrug-resistant Acinetobacter baumannii strains, isolated from respiratory samples in Spain

    Genome Announcements, Vol. 4, Núm. 2

  2. Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 8, pp. 4464-4470

  3. New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii

    Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 9, pp. 1207-1214

  4. Use of adjuvants in the treatment of Acinetobacter baumannii

    Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 2, pp. 153-155

2015

  1. Actividad in vitro e in vivo del inhibidor de la proteína de la membrana externa A (OmpA) frente a Acinetobacter baumannii sensible y resistente a colistina

    Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria, Núm. 4